Meta Health Limited Announces Rights Issue with Listing Approval from SGX-ST

Meta Health Limited, a Singapore-incorporated healthcare company, has taken a significant step forward in its proposed renounceable non-underwritten rights issue. The company announced on January 6, 2025, that it received the Listing and Quotation Notice (LQN) from the Singapore Exchange Securities Trading Limited (SGX-ST) for dealing in, listing, and quotation of up to 264,078,029 new ordinary shares on the Catalist board.

Key Highlights of the Announcement

• The rights issue involves up to 264,078,029 new ordinary shares in the capital of Meta Health Limited.
• The LQN was received on January 3, 2025, and is subject to the company’s compliance with SGX-ST’s listing requirements.
• The receipt of the LQN does not imply any endorsement of the merits of the rights issue, rights shares, or the company’s securities.
• An Offer Information Statement with further details will be disseminated to entitled shareholders in due course.

Important Notes for Shareholders

Shareholders and potential investors should note the following:

• The completion of the rights issue is not guaranteed and remains subject to specific conditions.
• The terms of the rights issue may still be subject to changes.
• Shareholders are advised to exercise caution when trading or dealing in the company’s shares.
• Further announcements regarding the Offer Information Statement and the rights issue will be made by the company as required.

Implications for Share Value

The rights issue could potentially impact share value depending on market reception, shareholder participation, and the eventual use of proceeds. While the LQN approval is a positive milestone, the uncertainty surrounding the completion of the rights issue necessitates investor prudence.

Cautionary Statement

The board of Meta Health Limited has emphasized the importance of shareholders and potential investors exercising caution. Those unsure about their course of action are encouraged to consult financial advisors, stockbrokers, or other professional advisors.

Company Statement

Gwendolin Lee Soo Fern, Company Secretary of Meta Health Limited, issued the announcement. The company’s sponsor, ZICO Capital Pte. Ltd., has reviewed the announcement but emphasized that the SGX-ST has neither examined nor approved its contents. Investors are reminded that the SGX-ST assumes no responsibility for the accuracy of the announcement.

For further inquiries, shareholders can contact ZICO Capital Pte. Ltd. at their office on 77 Robinson Road, Singapore, or via telephone at (65) 6636 4201.

Conclusion

Meta Health Limited’s rights issue marks a significant development for the company and its shareholders. However, the uncertainty surrounding its completion and potential changes to its terms means investors should closely monitor the situation and await further updates.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Readers are encouraged to consult with professional advisors before making any investment decisions. The author and publisher assume no responsibility for any financial decisions made based on this article.